Individual tailored chemotherapy

Tumori

Volumn 1, Issue 6 SUPPL., 2002, Pages

  Beretta, Giordano D ^a   Labianca, Roberto ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CETUXIMAB; CYTOCHROME P450; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; RITUXIMAB; TAXANE DERIVATIVE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE NEU;

EID: 0036836773     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916020016s108     Document Type: Conference Paper

References (23)

1. Kohne CH, Cunningham D, Di Costanzo F et al: Clinical determinants of survival in patients with 5fluorouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol, 13: 308-317, 2002.
2. Knight RD, Miller RR, Pirotta N et al: Firstline irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favourable prognostic indicators. Proc Am Soc Clin Oncol, 19: abst 991, 2000.
3. Beretta GD, Ferrari VD, Barni S et al: Medical treatment of colorectal cancer in elderly (>70 years): GISCAD experience and future perspectives. Tumori, 88: S109-S112, 2002.
4. Druker BJ for the IRIS Study Group: STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CIVIL: results of a randomised study. Proc Am Soc Clin Oncol, 21: abst 1, 2002.
5. Slamon DJ, Godolphin W, Jones LA et al: Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science, 244: 707-712, 1999.
6. Hortobagyi GN: Options for treatment of metastatic breast cancer. ASCO Educational Session, 515-521, 1999.
7. Cobleigh MA, Vogel CL, Tripathy D et al: Efficacy and safety of Herceptin (humanized antiHER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol, 17: abst 97, 1998.
8. Baselga J, Norton L, Albanell J et al: Recombinant humanized antiHER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing metastatic breast cancer xenografts. Cancer Res, 58: 2825-2831, 1998.
9. Gusterson BA, Gelber RD, Goldhirsch A et al: Prognostic importance of cerbB2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10: 1049-1056, 1992.
10. Muss HB, Thor AD, Berry DA et al: cerbB2 expression and response to adjuvant therapy in women with nodepositive early breast cancer. N Engl J Med, 330: 1260-1266, 1994.
11. Aschele C, Lonardi S, Monfardini 5: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidinebased chemotherapy in advanced colorectal cancer. Cancer Treat Rev, 28: 2747, 2002.
12. Etienne MC, Chazal M, Puig PL et al: Prognostic value of tumoral thymidylate syntase and p53 in metastatic colorectal cancer patients receiving fluorouracilbased chemotherapy: phenotypic and genotypic analyses. J Clin Oncol, 20: 2832-2843, 2002.
13. Edler D, Glimelius B, Hallstrom M et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracilbased chemotherapy. J Clin Oncol, 20: 1721-1728, 2002.
14. Salz L, Rubin M, Hochster H et al: Cetuximab (IMCC225) plus irinotecan (CPT 11) is active in CPT Il refractory colorectal cancer (CRC) that expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol, 20: abst 7, 2001.
15. Salz L, Meropol NJ, Loehrer PJ et al: Single agent IMCC225 (Erbitux TM has activity in CPT ilrefractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol, 21: abst 504, 2002.
16. Rosemberg AH, Loehrer PJ, Needle MN et al: Erbitux (IMCC225) plus weekly irinotecan (CPT Il), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol, 21: abst 536, 2002.
17. Scagliotti GV: Tyrosine kinase signal transduction inhibitors. Clinical trials. Tumori, 88: S35-S36, 2002.
18. Herbst RS: ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs, 11: 837-849, 2002.
19. Bergh J, Wiklund T, Erikstein B et al: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported highdose chemotherapy as adjuvant treatment for highrisk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet, 356: 1384-1391, 2000.
20. Petricoin E: Application of proteomic technology to human breast cancer at the bedside multiplexed signal pathway profiling. Proc Am Assoc Cancer Res, 21: abst 681, 2002.
21. Gardener SN: Modeling multidrug chemotherapy: tailoring treatment to individuals. J Theor Biol, 214: 181-207, 2002.
22. Steinmetz ND: Early prediction of tumor chemotherapy response and prognosis based on Tc99m annessin V (Apomatem) imaging after one course of chemotherapy. Proc Am Assoc Cancer Res, 21: abst 4136, 2002.
23. Schott AF, Taylor J, Baker L et al: Individualized chemotherapy dosing based on metabolic phenotype. Proc Am Soc Clin Oncol, 20: abst 306, 2001.